Segment 3 - Pairing Patients with the Right Therapies

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

Dr Shafer-Weaver explains that with CTLA-4, melanoma responds well to immunotherapy, but there is work being done currently regarding PD-1 and PD-L1. Results show that even though PD-L1 negative tumor respond well, patients highly express PD-L1 respond better.

“I think the biggest thing right now is there is no consistency in the field, and so I think it is kind of hard right now at this stage to get a grasp on that because we do not have standardized assays that all labs do the same,” she said. “It is not a common thing; specialized labs do that.”